NSE-listed pharmaceutical and device companies investing in GLP-1 receptor agonist manufacturing — from peptide API production to semaglutide pen delivery systems.
Sectors represented: Healthcare, Capital Goods
So it's a doubling of capacity that we have just. completed, and we will go through the regulatory approval process to bring that product. to patients. manufacturing drug product twofold. So it's a doubling of capacity that we have just. completed, and we will go through the regulatory approval process to bring that product. to patients.
CEP certification, while an import-substitute non-. oncology API completed validation and is expected. to be commercialised in FY27. Capacity expansion. for UDCA and Tranexamic Acid is also underway. while an import-substitute non-. oncology API completed validation and is expected. to be commercialised in FY27. Capacity expansion. for UDCA and Tranexamic Acid is also underway. In.
Created a strategic stock of Insulins - consequent. working capital increase of Rs. 73 cr. in Q1 with an. impact on OCF for the quarter. . Bhopal vial manufacturing has been commissioned. after significant delays. . . Initiated supply of Insugen vials from MJ Biopharm's al increase of Rs. 73 cr. in Q1 with an. impact on OCF for the quarter. . Bhopal vial manufacturing has been commissioned.
Shaily Axiom Max, a fixed-dose pen, in the second quarter of. FY 25-26; it now took its place within a four-platform portfolio. alongside Neo, Harmony and Toby. he 21st consecutive year of recognition. Shaily Axiom Max, a fixed-dose pen, in the second quarter of. FY 25-26; it now took its place within a four-platform portfolio. alongside Neo, Harmony and Toby. To take the business ahead,.
It would take some time for us to completely utilize 140 million. But this is. what the visibility as of now. Srinivas Sadu:. So as of now capacity is 40 million just to be clear, and then 100 million is getting added this. year. us to completely utilize 140 million. But this is. what the visibility as of now. Srinivas Sadu:.
Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹89.898 and accordingly the prior period figures have been restated. 1. de fully provided in. FY26 financials. Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹89.898 and accordingly the prior period figures have been restated. 1.
Unique competitive edge with GLP-1 is a significant factor for future success while the biologics. business has also picked up. 33. ▷FromalowbaseinFY20,wehaveaddedseveralnew. customersafterreceivingUSFDAapprovalinFY23(Two. inspectionsincludedinCY2022-PAI,DrugDevice,andGMP). ▷Ourbusinesscontinuestogrowaswepropelourgeographical. marketingeffortsandattractnewpartners.
Our R&D formulation team, leverages. state-of-the art infrastructure including. high-pressure/high-shear homogenisation,. zeta sizers, and viscometers—to develop. a diversified, high-quality portfolio of. simple and complex products across. oral, ophthalmic, and topical routes of. administration. For Oral Solid Dosage (OSD) forms, we. utilise advanced granulators, compression.
Erez Israeli: Yeah, I believe so. You can see that by the fact that Lenalidomide is going down, we are. maintaining reasonably low numbers. or this to. actually show up in numbers?. Erez Israeli: Yeah, I believe so. You can see that by the fact that Lenalidomide is going down, we are. maintaining reasonably low numbers. So, it's absolutely a reflection of those mitigations. Of.